Nico launches trial for brain surgery shunt

Nico Corp said today it enrolled the 1st patient in the Enrich clinical trial which aims to explore the use of its BrainPath Approach for treating intracerebral hemorrhages. The trial will examine the procedural safety as well as economic and functional benefit of early surgical removal of intracerebral hemorrhages using its BrainPath Approach system. “Our initial clinical results with this approach for early clot removal have been exciting and provided a wake-up call to what has been missing in hemorrhagic stroke care,” trial principal investigator Dr. Daniel Barrow said in a press release. Indianapolis, Ind.-based Nico said it hopes to enroll 300 spontaneous supratentorial ICH patients in the trial at 15 trial sites as it studies the system. “We are seeing encouraging results with our patients and added economic benefit to our hospital. This trial will help us determine in a scientifically valid manner if a precise surgical technique to avoid additional injury to the brain and early evacuation of blood contributes to improved clinical and functional outcomes,” study principal investigator Dr. Gustavo Pradilla said in a prepared statement. The Enrich trial will compare the standard of care, which is medical management of the siituation, to early surgical evacuation using a parafascicular and trans-sulcal surgical approach for clot removal and hemostasis. “Scientific evidence from prospective and retrospective studies has produced strong cli...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Neurological Nico Corp. Source Type: news